Call to action
The following organisations support and endorse our call to action:
By 2025, it is estimated that 4.5 million fragility fractures will occur in the European Union (EU) each year, and that 34 million people will be living with osteoporosis, a chronic disease which weakens bones and leaves people at risk of a fragility fracture.1
Few diseases affect so many of us as we grow older: approximately 1 in 2 women and 1 in 5 men in Europe over 50 years of age will experience a fragility fracture in their lifetime1 – often leading to a loss of mobility and independence.2
This represents a huge economic burden. Fragility fractures in 2010 were estimated to cost €37.4 billion to EU healthcare systems, which accounted for around 3% of healthcare costs, significantly higher than for many other leading chronic diseases.1 3
Yet osteoporosis and fragility fractures have for too long been ignored in health policy and European research agendas.4 5 Even policies, strategies and programmes that focus on healthy ageing and women’s health may ignore the impact of osteoporosis and fragility. This has left millions of people – mostly women – without access to the care and support they need to live full, independent lives.
By prioritising osteoporosis and fragility fractures, gender differences in health and wellbeing can be reduced. In addition, the quality of life of older people can be enhanced and the financial sustainability of our already stretched healthcare systems can be strengthened.
As the authors, contributors and supporters of this policy toolkit, we cannot accept a future where preventable fragility fractures are allowed to cause such needless suffering and cost. The time has come for urgent action on osteoporosis and fragility fractures, uniting patient, carer and clinical leadership with wider societal and political advocacy actors in order to strengthen the call for change.
We endorse the policy aspirations of the International Osteoporosis FoundationThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue and the Fragility Fracture NetworkThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue’s global call to action6 and seek to play our part in building wider societal and political awareness for progress and change. We have developed specific calls to action for European institutions, national leadership and regional and local systems.
Call to action for European institutions
The European Union should recognise the scale of societal and structural interests at stake, and foster strategic cooperation between countries.
European institutions, including the European Commission (in cooperation with member states) and the European Parliament, should:
- Continue to support the European Innovation Partnership on Active and Healthy AgeingThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue as a coordination platform which allows partners to pool resources and share experiences in pursuit of innovative solutions to healthy and active ageing. Support for the partnership should continue beyond 2020 and consider widening its scope to include fragility fracture prevention.
- Continue to invest in Joint Actions which support the prevention of fragility fractures and falls.7 The CHRODIS+ Joint Action on chronic diseaseThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue and the ADVANTAGE Joint Action on frailtyThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue both end in 2020.8 9 Future initiatives should include a focus on osteoporosis and the prevention and management of fragility fractures.
- Ensure osteoporosis and fragility fractures are included in eligible activities funded under the European Social Fund PlusThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue (ESF+).10 ESF+ activities in health must support member states to recognise the central role of improving prevention and care for osteoporosis, fragility fractures and falls.
- Include prevention of fragility fractures in the joint Organisation for Economic Co-operation and Development (OECD)/European Commission publication Health at a Glance: EuropeThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue11 as well as the ‘State of Health in the EU’ cycle. Although time to surgery following hip fractures is included, prevention of fractures must also be prioritised.
- Ensure specific attention for osteoporosis and fragility fractures by the Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable DiseasesThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue and the Expert Panel on Effective Ways of Investing in HealthThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue.12 13 Statements and recommendations could be prepared to specifically support improved identification and management of osteoporosis through screening and effective fragility fracture prevention.
- Prioritise fragility fracture and falls prevention in European-level occupational health and safety initiatives. The EU’s Occupational Safety and Health Strategic FrameworkThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue,14 as well as future initiatives in this domain, must recognise the importance of reducing falls at work and propose concrete measures to minimise fragility fractures among older workers.
- Support and coordinate pan-European research on osteoporosis and fragility fractures via Horizon Europe’sThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue health cluster.15 Research could be devoted to gaining a better understanding of the methods for identifying people at risk of fragility fractures and to testing innovative prevention and care models.
- Support activities in the European Parliament which seek to address osteoporosis and fragility fractures. Concerned stakeholders could, for example, seek interest from MEPs in the formation of an interest group on osteoporosis and fragility fractures.
Call to action for national leadership
Historical failures in the care of osteoporosis and the prevention of fragility fractures are profound and will not be resolved without political, whole‑system leadership.
We call on policymakers to ensure public policy is fit for purpose in light of future demands. Specifically, we call on governments, parliaments, payers and national public health institutes to, at a minimum:
- Integrate osteoporosis, fragility fractures and falls prevention into high-level national strategies and plans for health and healthcare, including those which aim to address chronic diseases and women’s health.
- Acknowledge the huge significance of fragility fractures by ensuring they are integrated into wider societal plans, including those for population health, healthy ageing, long-term care including informal care, and workforce productivity.
- Develop a national consensus on preventing fragility fractures through more systematic identification of people with osteoporosis. This should include consideration of screening specific groups. Any national decision on screening must be based on national epidemiological and economic data, including the feasibility and cost-effectiveness of integrating osteoporosis screening alongside other screening programmes, such as those for breast cancer.
- Adopt and encourage the implementation of clinical guidelines for osteoporosis and fragility fracture prevention and care. These guidelines should be available in the national language and, at a minimum, include nationally approved risk assessment tools, as well as timely referral and access to osteoporosis diagnosis.
- Ensure that reimbursement structures reflect national scientific consensus on detection, care and prevention of osteoporosis and fragility fractures. Reimbursement decisions should reflect the true costs of fragility fractures to the wider healthcare system and society. At a minimum, there should be reimbursement for nationally recommended diagnostic tools (such as dual-energy X-ray absorptiometry (DXA) scanning and the Fracture Risk Assessment Tool (FRAXThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue) and treatments.
- Develop nationwide registries and audits to enable local-level monitoring and surveillance of patient health outcomes. This should include collecting and monitoring data on the diagnosis of osteoporosis and for the prevention and care of fragility fractures, spanning hip and vertebral fractures at a minimum. Policymakers should also consider how these data could be used to incentivise improvements in the quality of care.
- Actively support efforts to improve public awareness of osteoporosis, fragility fractures and falls prevention. This includes ensuring people have a clear understanding of their personal risk factors and the preventive options available to them.
Call to action for regional and local systems
Improvements to people’s lives will ultimately be driven by improved access to appropriate prevention and care at a local level.
We call on health system leaders, including payers and the medical community, to invest in sustainable, multidisciplinary care models for osteoporosis, fragility fractures and falls prevention, which span hospital, primary and community care settings. This will require:
- Primary care professionals to take a leadership role in the detection, management and care of osteoporosis and fragility fractures. Specific roles and responsibilities in primary care should be developed with professional bodies and payers. Delegation to other roles (e.g. pharmacists, specialist nurses and physiotherapists) should be considered alongside requirements for professional education and training for all involved.
- Every locality to develop and adopt an osteoporosis and fragility fracture care pathway. This should include the development of local criteria to establish to whom the pathway should be applied.
- Ensuring the availability of person-centred multidisciplinary models of care with demonstrated impact on reducing the risk of repeat fractures and death. At the very least, every general hospital should offer orthogeriatric services and a coordinated follow-up service (e.g. fracture liaison service) so that every fracture patient has the option to be treated or referred there for care and immediate follow-up post-fracture. This care should be delivered in a way that addresses people’s needs and respects their preferences.
- Ensuring that a comprehensive falls assessment is available for every geriatric patient. This should be available in clinical settings as well as community settings (such as specialist housing and people’s own homes) and offer the opportunity for self-assessment. It should bring together multidisciplinary input and risk factor management for falls alongside detection and treatment of osteoporosis.
Date of preparation: October 2020.
- Hernlund E, Svedbom A, Ivergard M, et al. 2013. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of osteoporosis 8: 136
- Ross PD. 1997. Clinical consequences of vertebral fractures. The American journal of medicine 103(2a): 30S-42S; discussion 42S-43S
- Wilkins E, Wilson L, Wickramasinghe K, et al. 2017. European cardiovascular disease statistics 2017. Brussels: European Heart Network
- European League Against Rheumatism (EULAR). 2017. RheumaMap. A Research Roadmap to transform the lives of people with Rheumatic and Musculoskeletal Diseases. Brussels: EULAR
- Briggs AM, Persaud JG, Deverell ML, et al. 2019. Integrated prevention and management of non-communicable diseases, including musculoskeletal health: a systematic policy analysis among OECD countries. BMJ Global Health 4(5): e001806
- Dreinhöfer KE, Mitchell PJ, Bégué T, et al. 2018. A global call to action to improve the care of people with fragility fractures. Injury 49(8): 1393-97
- European Innovation Partnership on Active and Healthy Ageing. Welcome to the EIP on AHA portal. Available from: www.ec.europa.eu/eip/ageingThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 06/10/20]
- Chrodis Plus. Chrodis+: Implementing good practices for chronic diseases. Available from: www.chrodis.euThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 03/12/19]
- Joint Action European Union. 2019. ADVANTAGE JA -A comprehensive approach to promote a disability-free Advanced age in Europe: the ADVANTAGE initiative. Available from: www.advantageja.eu/index.php/about-us/what-is-jaThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 01/09/20]
- European Commission. European Social Fund. Available from: www.ec.europa.eu/esfThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 07/10/20]
- OECD/EU. 2018. Health at a glance: Europe 2018: State of health in the EU cycle. Paris: Publishing O
- European Commission. Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases. Available from: www.ec.europa.eu/health/non_communicable_diseasesThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 07/10/20]
- European Commission. Expert Panel on effective ways of investing in health: Overview. Available from: www.ec.europa.eu/health/exph/overviewThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 07/10/20]
- European Agency for Safety and Health at Work. OSH strategies. Available from: www.osha.europa.eu/en/safety-and-health-legislation/osh-strategiesThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 07/10/20]
- European Commission. Horizon Europe – the next research and innovation framework programme. Available from: www.ec.europa.eu/info/horizon-europe-next-research-and-innovation-framework-programme_enThis link opens a new tab and sends you to a website not owned by Amgen (Europe) GmbH. Click here to continue [Accessed 07/10/20]